Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial

被引:11
|
作者
Boschheidgen, Matthias [1 ]
Albers, Peter [2 ,3 ]
Schlemmerd, Heinz -Peter [4 ]
Hellms, Susanne [5 ]
Bonekamp, David [4 ]
Sauterf, Andreas [6 ]
Hadaschikg, Boris [7 ,8 ]
Krilaviciute, Agne [3 ]
Radtke, Jan Philipp [2 ]
Seibold, Petra [3 ]
Lakes, Jale [2 ]
Arsov, Christian [2 ,9 ]
Gschwend, Juergen E. [10 ]
Herkommeri, Kathleen [10 ]
Makowsk, Marcus [6 ]
Kuczyk, Markus A. [10 ]
Wacker, Frank [5 ]
Harke, Nina [11 ]
Debus, Juergen [3 ,12 ]
Korber, Stefan A. [3 ,12 ]
Benner, Axel [4 ,13 ]
Kristiansen, Glen [14 ]
Giesel, Frederik L. [15 ]
Antoch, Gerald [1 ,16 ]
Kaaksp, Rudolf [17 ]
Beckerc, Nikolaus [3 ]
Schimmoelleraq, Lars [1 ,18 ]
机构
[1] Dusseldorf Univ, Med Fac, Dept Diagnost & Intervent Radiol, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Med Fac, Dept Urol, D-40225 Dusseldorf, Germany
[3] German Canc Res Ctr, Div Personalized Early Detect Prostate Canc, Heidelberg, Germany
[4] German Canc Res Ctr, Dept Radiol, Heidelberg, Germany
[5] Inst Diagnost & Intervent Radiol, Hannover Med Sch, Hannover, Germany
[6] Tech Univ Munich, Sch Med, Dept Diagnost & Intervent Radiol, Klinikum Rechts Isar, Munich, Germany
[7] Univ Duisburg Essen, Dept Urol, Essen, Germany
[8] Univ Hosp Essen, German Canc Consortium dktk, Essen, Germany
[9] Elisabeth Krankenhaus Rheydt, Dept Urol & Paediat Urol, Stadt Kliniken Monchengladbach GmbH, Monchengladbach, Germany
[10] Tech Univ Munich, Sch Med & Hlth, Dept Urol, Munich, Germany
[11] Hannover Med Sch, Dept Urol, Hannover, Germany
[12] Heidelberg Univ Hosp, Ruprecht Karls Univ, Dept Radiat Oncol, Heidelberg, Germany
[13] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
[14] Univ Hosp Bonn, Inst Pathol, Bonn, Germany
[15] Univ Dusseldorf, Med Fac, Dept Nucl Med, D-40225 Dusseldorf, Germany
[16] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldor, Dusseldorf CIO ABCD, Dusseldorf, Germany
[17] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany
[18] Univ Bochum, Univ Hosp Ruhr, Marien Hosp Herne, Dept Diagnost, Herne, Germany
关键词
Prostatic neoplasms; Screening; Multiparametric magnetic resonance imaging; Magnetic resonance imaging; Interventional; MEN; MRI;
D O I
10.1016/j.eururo.2023.09.027
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Magnetic resonance imaging (MRI) has been suggested as a tool for guiding biopsy recommendations in prostate cancer (PC) screening. Objective: To determine the performance of multiparametric MRI (mpMRI) in young men at age 45 yr who participated in a PC screening trial (PROBASE) on the basis of baseline prostate-specific antigen (PSA). Design, setting, and participants: Participants with confirmed PSA >= 3 ng/ml were offered mpMRI followed by MRI/transrectal ultrasound fusion biopsy (FBx) with targeted and systematic cores. mpMRI scans from the first screening round for men randomised to an immediate PSA test in PROBASE were evaluated by local readers and then by two reference radiologists (experience >10 000 prostate MRI examinations) blinded to the histopathology. The PROBASE trial is registered as ISRCTN37591328 Outcome measurements and statistical analysis: The local and reference Prostate Imaging-Data and Reporting System (PI-RADS) scores were compared, and the sensitivity, negative predictive value (NPV), and accuracy were calculated for both readings for different cutoffs (PI-RADS 3 vs 4). Results and limitations: Of 186 participants, 114 underwent mpMRI and FBx. PC was detected in 47 (41%), of whom 33 (29%) had clinically significant PC (csPC; International Society of Urological Pathology grade group >= 2). Interobserver reliability between local and reference PI-RADS scores was moderate (k = 0.41). At a cutoff of PI-RADS 4, reference reading showed better performance for csPC detection (sensitivity 79%, NPV 91%, accuracy of 85%) than local reading (sensitivity 55%, NPV 80%, accuracy 68%). Reference reading did not miss any PC cases for a cutoff of PI-RADS <3. If PI-RADS >= 4 were to be used as a biopsy cutoff, mpMRI would reduce negative biopsies by 68% and avoid detection of nonsignificant PC in 71% of cases. Conclusions: Prostate MRI in a young screening population is difficult to read. The MRI accuracy of for csPC detection is highly dependent on reader experience, and double reading might be advisable. More data are needed before MRI is included in PC screening for men at age 45 yr.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 50 条
  • [1] Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol.
    Huang, Tian-Bao
    Ding, Xue-Fei
    EUROPEAN UROLOGY, 2024, 85 (04) : e112 - e112
  • [2] Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial
    Ortegon, Jose D. Cardona
    Perilla, Laura A. Campana
    Bermudez, Laura M. Olarte
    EUROPEAN UROLOGY, 2024, 86 (01)
  • [3] Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Goteborg Prostate Cancer Screening 2 Trial
    Wallstrom, Jonas
    Geterud, Kjell
    Kohestani, Kimia
    Maier, Stephan E.
    Pihl, Carl-Gustaf
    Socratous, Andreas
    Stranne, Johan
    Arnsrud-Godtman, Rebecka
    Mansson, Marianne
    Hellstrom, Mikael
    Hugosson, Jonas
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (01): : 54 - 60
  • [4] A Randomized Trial of Risk-Adapted Screening for Prostate Cancer in Young Men - Updated Results of the First Screening Round of the PROBASE Trial
    Albers, Peter
    Arsov, Christian
    Lakes, Jale
    Radtke, Jan Philipp
    Herkommer, Kathleen
    Gschwend, Jürgen
    Peters, Inga
    Kuczyk, Markus
    Koerber, Stefan
    Debus, Jürgen Peter
    Hadaschik, Boris
    Kristiansen, Glen
    Schimmoeller, Lars
    Antoch, Gerald
    Rummeny, Ernst
    Makowski, Marcus
    Wacker, Frank
    Schlemmer, Heinz
    Benner, Axel
    Siener, Roswitha
    Kaaks, Rudolf
    Becker, Nikolaus
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 42 - 42
  • [5] A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial
    Arsov, Christian
    Albers, Peter
    Herkommer, Kathleen
    Gschwend, Juergen
    Imkamp, Florian
    Peters, Inga
    Kuczyk, Markus
    Hadaschik, Boris
    Kristiansen, Glen
    Schimmoeller, Lars
    Antoch, Gerald
    Rummeny, Ernst
    Wacker, Frank
    Schlemmer, Heinz
    Benner, Axel
    Siener, Roswitha
    Kaaks, Rudolf
    Becker, Nikolaus
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (11) : 1861 - 1869
  • [6] Risk-Adapted Screening for Prostate Cancer in Young Men - First Results of the Probase Trial
    Albers, Peter
    Arsoy, Christian
    Herkommer, Kathleen
    Gschwend, Juergen
    Imkamp, Florian
    Kuczyk, Markus A.
    Hadaschik, Boris
    Kristiansen, Glen
    Schimmoeller, Lars
    Antoch, Gerald
    Rummeny, Ernst
    Wacker, Frank K.
    Schlemmer, Heinz-Peter
    Benner, Axel
    Siener, Roswitha
    Kaaks, Rudolf
    Becker, Nikolaus
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 211 - 211
  • [7] Screening for prostate cancer: Results about first screening round from the French population of the ERSPC trial
    Richard, F.
    PROGRES EN UROLOGIE, 2009, 19 (07): : 499 - 500
  • [8] Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial
    Krilaviciute, Agne
    Albers, Peter
    Lakes, Jale
    Radtke, Jan Philipp
    Herkommer, Kathleen
    Gschwend, Jurgen
    Peters, Inga
    Kuczyk, Markus
    Koerber, Stefan A.
    Debus, Jurgen
    Kristiansen, Glen
    Schimmoller, Lars
    Antoch, Gerald
    Makowski, Marcus
    Wacker, Frank
    Schlemmer, Heinz
    Benner, Axel
    Giesel, Frederik
    Siener, Roswitha
    Arsov, Christian
    Hadaschik, Boris
    Becker, Nikolaus
    Kaaks, Rudolf
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (05) : 854 - 864
  • [9] Future of screening for prostate cancer Multiparametric magnetic resonance imaging is likely to be part of it
    Dahm, Philipp
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 358
  • [10] Results of the second screening round of the Finnish prostate cancer screening trial
    Tammela, TL
    Määttänen, L
    Stenman, UH
    Rannikko, S
    Juusela, H
    Aro, J
    Hakama, M
    Auvinen, A
    JOURNAL OF UROLOGY, 2002, 167 (04): : 100 - 100